At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 140 enrolled
Drug / intervention
Deferiprone +1 moredrug
Likely dose
Deferiprone 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating Deferiprone and Placebo for Parkinson's Disease. Completed, enrolled 140 participants across 20 sites in 4 countries.
Detailed Summary
The goal of this study is to evaluate the effects of deferiprone, an iron-chelating drug, in patients with Parkinson's disease. Participants will be randomized to receive one of four different dosages of deferiprone or placebo, and will take the assigned study product twice a day for nine months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesCanada, France, Germany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartOct 2016
Primary CompletionAug 2019
Study CompletionSep 2019
TodayJul 2026
First PostedApr 5, 2016
Enrollment StartOct 12, 2016
Primary CompletionAug 2, 2019
Study CompletionSep 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.2 years ago
Interventions
Deferipronedrug
600 mg tablets
Placebodrug
Tablets that match the deferiprone tablets in appearance